Stamford Therapeutics Consortium (STC) is a privately owned and operated clinical research site specializing in phase II, III, and IV clinical trials for the pharmaceutical and biotechnology industries. Operating as an independent investigational site since its founding in 1994, the company’s sole mission is to conduct the highest quality clinical trials so that new, safe and effective medications can be developed, researched and approved for a variety of indications and diseases.
STC has a strong working relationship with a cardiology group, a large multispecialty medical practice, and a team of physicians who serve as sub-investigators for many of its clinical trials. STC maintains a significant presence in research for the treatment of osteoarthritis and rheumatoid arthritis, while continuing to expand its research into new therapeutic areas. Year after year STC's list of specialties grows to accommodate a growing demand and new innovations in healthcare.
With over 15 years of clinical trials operations, STC has conducted more than 350 national and multi-national clinical trials.